Senolytics are a class of drugs that can selectively eliminate senescent cells, which are cells that have stopped dividing and are no longer able to perform their functions.

Senescent cells, also known as ‘zombie cells‘ can accumulate with age and contribute to the onset of age-related diseases and decline in function.

Senolytic drugs are currently being developed and tested as a potential treatment for age-related diseases and conditions including cardiovascular disease, osteoarthritis, and diabetes.

You missed:   What I’ve learnt: Jeremy King, founder and CEO of Attest

There is no scientific evidence to suggest that senolytic drugs can extend one’s life, they show promise as a potential treatment for age-related diseases and conditions, it is too early to say whether they will have any effect on lifespan.

There is some evidence to suggest that senolytic drugs show viability in being  able to slow down certain aspects of aging.

You missed:   Deliveroo enters supply chain sector with ‘Food Procurement’ service

One study found that senolytic drugs were able to reduce the number of senescent cells in mice and improve their physical function and healthspan (i.e., the length of time that an individual remains healthy). However, it is important to note that this study was conducted in mice and it is not yet known whether senolytic drugs will have the same effects in humans.

You missed:   KPMG UK appoints new head of private enterprise sector

It is also important to be aware of the potential risks and limitations of any new medical treatment, including senolytic drugs.

As with any experimental treatment, there is a possibility that senolytic drugs may not be effective or may have unintended side effects. It is important for the safety and effectiveness of any new treatment to be thoroughly tested in clinical trials before it is made available to the public.